HRAS and head and neck squamous cell carcinoma: Although the FDA rejected its approval for acute myeloid leukemia (AML), tipifarnib has shown promise in HRAS-mutant head and neck squamous cell carcinoma (HNSCC) (NCT02383927), and in January 2021, the FDA granted a breakthrough therapy designation (BTD) to Zarnestra [132].